Chen M. J. (2020). Normal tension glaucoma in Asia: Epidemiology, pathogenesis, diagnosis, and management. Taiwan journal of ophthalmology, 10(4), 250–254. https://doi.org/10.4103/tjo.tjo_30_20
Chauhan BC, Mikelberg FS, Balaszi AG, et al. CanadianGlaucoma Study: 2. risk factors for the progression of open-angle glaucoma. Arch Ophthalmol 2008; 126(8): 1030-6.
Heijl A. Glaucoma treatment: by the highest level of evidence.Lancet 2015; 385(9975): 1264-6.
Leske MC, Heijl A, Hyman L, et al. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15(2): 102-6.
Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in thetreatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99(6): 738-45.
Kawase K, Vittitow JL, Weinreb RN, et al. Long-term Safetyand Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. Adv Ther 2016; 33(9): 1612-27.
